Monte Rosa Therapeutics

Filed a patent for "targeted protein degradation" on Tue, July 25, 2023

Filed a patent for "targeted degradation of vav1" on Mon, January 9, 2023

Filed a patent for "programmable e3 ligase identification" on Wed, May 17, 2023

Filed a patent for "degron and neosubstrate identification" on Tue, May 14, 2024

Filed a patent for "compounds that mediate protein degradation and methods of use thereof" on Thu, September 26, 2024

Filed a patent for "methods of desiging molecular glue degraders" on Fri, October 21, 2022

Filed a patent for "degron identification using neural networks" on Wed, October 26, 2022

Filed a patent for "compounds that mediate protein degradation and methods of use thereof" on Wed, October 26, 2022

Filed a patent for "degron and neosubstrate identification" on Wed, October 26, 2022

Filed a patent for "isoindolinone compounds" on Thu, November 2, 2023

Filed a patent for "treatment of myc-driven cancers with gspt1 degraders" on Wed, July 12, 2023

Filed a patent for "isoindolinone amide compounds useful to treat diseases associated with gspt1" on Thu, February 15, 2024

Filed a patent for "isoindolinone compounds" on Thu, February 15, 2024

Filed a patent for "e3 ligase fusion proteins for proximity detection" on Wed, November 29, 2023

Filed a patent for "molecular glue degraders and methods of using the same" on Thu, June 16, 2022

Filed a patent for "molecular glue degraders and methods of using the same" on Thu, June 16, 2022

Filed a patent for "molecular glue degraders and methods of using the same" on Thu, June 16, 2022

Filed a patent for "combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors" on Wed, July 13, 2022

Filed a patent for "methods of preparing compounds" on Thu, July 14, 2022